Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14133842 | 0.97 | TDP1 (0.35) | TDP1L3MBTL1CYP1A1CYP1A2FYN | |
| SCHEMBL14133912 | 0.94 | TDP1 (0.33) | TDP1L3MBTL1CYP1A1CYP1A2FYN | |
| SCHEMBL26335569 | 0.94 | TDP1 (0.36) | TDP1L3MBTL1CYP1A1CYP1A2FYN | |
| SCHEMBL26335546 | 0.94 | ANO1 (0.32) | TDP1L3MBTL1CYP1A1CYP1A2 | |
| SCHEMBL26339536 | 0.94 | PLA2G2A (0.33) | TDP1L3MBTL1 | |
| SCHEMBL26335393 | 0.94 | HCRTR1 (0.33) | TDP1L3MBTL1CYP1A1CYP1A2 | |
| SCHEMBL26335444 | 0.94 | ANO1 (0.32) | TDP1L3MBTL1CYP1A1CYP1A2 | |
| SCHEMBL26337009 | 0.94 | PLA2G2A (0.32) | TDP1L3MBTL1CYP1A1CYP1A2 | |
| SCHEMBL26335360 | 0.93 | ESR1 (0.33) | TDP1L3MBTL1CYP1A2 | |
| SCHEMBL26336260 | 0.91 | CA1 (0.33) | TDP1CYP1A1CYP1A2AHRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301176-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENTS, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230301176-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENTS, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230301176-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENTS, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | LEF1, ELAVL1, PIEZO1 | TDP1 2135/4885L3MBTL1 452/4885CYP1A1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.